Diagnostic accuracy
Rising frailty flags one-year death risk
Open access · cc by · source: Europe PMC
Rapid monthly rises in the electronic frailty index marked older adults twice as likely to die within a year, with high specificity.
Study at a glance
- Design
- Cohort — English primary-care EHR; monthly eFI trajectories before death vs matched controls
- N
- N=26298 · 13,149 decedents and 13,149 matched controls
- Population
- English primary-care patients with electronic frailty index trajectories
- Outcome
- 12-month mortality risk by rapidly rising vs stable frailty class
Structured fields used in claim comparison tables when every cited study has a complete layer.
Key findings
Rapidly rising frailty (≈0.01 eFI/month) doubled 12-month death risk vs stable frailty; reweighted, this class (~1.1% of population) predicted 1-year mortality with 99.1% specificity.
Methodology
Using English primary-care EHR data, researchers compared monthly eFI trajectories for 13,149 decedents and matched controls (n=26,298) over the year before death or a pseudo-end date.
Limitations
That eFI alone should replace clinical judgment, or that intervening on trajectory class improves end-of-life care outcomes.
How this study connects
Role on claims
Each row is a claim on a concept or method page where this paper supports, challenges, or qualifies the statement. Roles are hand-checked — not a model guess.
Higher blood GFAP and NfL associate with later dementia risk — prognosis, not same-day diagnosis.
In UK Biobank, higher baseline plasma GFAP and NfL were associated with roughly doubled hazards of incident dementia over ~13 years, with incremental discrimination when added to demographic risk scores—prognostic biomarker performance, not a bedside diagnostic rule-in test.
Scope note — related prognostic framing — frailty trajectory vs death, not plasma NfL
Limits the claim's scope: a different population, assay, or outcome.
Other tools (sickle cell, pain subtype, frailty trajectories) answer their own accuracy questions.
Other validated tools in this set include a point-of-care sickle-cell device detecting HbS/HbC at low percentages suitable for neonates, StEP pinprick signs highly sensitive/specific for neuropathic vs non-neuropathic pain in specialist clinics, and rapidly rising electronic frailty index trajectories associated with doubled 12-month mortality versus stable frailty.
Evidence for the claim as stated.
In English primary-care EHR data, rapidly rising frailty (about 0.01 eFI per month) doubled 12-month death risk versus stable frailty among 13,149 decedents matched to 26,298 controls. Reweighted, that rare class (about 1.1% of the population) predicted 1-year mortality with 99.1% specificity. High specificity for a tiny stratum is not a reason to replace clinical judgment or to assume that intervening on trajectory class improves end-of-life care.
Evidence for the claim as stated.
The five papers are tuned to different prevalences and harms of error, so a 'good' sensitivity/specificity pair is not portable. CA125's 77%/93.8% at 0.9% incidence yields PPV 10.1% — a primary-care rare-disease problem. StEP's 95%/93% pinprick figures come from specialist clinics where neuropathic pain is common. FibriCheck's 95.6%/96.6% is versus ECG after dropping poor signals. Blood-culture 99.4%/99.7% is laboratory identification, not community screening. Frailty's 99.1% specificity describes a ~1.1% trajectory class, not a test you run on everyone.
Evidence for the claim as stated.
Open questions
Tensions this paper is part of
From concept pages' “where studies disagree.” Disagreement means the same question; scope means different assays, populations, or outcomes.
The five papers are tuned to different prevalences and harms of error, so a 'good' sensitivity/specificity pair is not portable. CA125's 77%/93.8% at 0.9% incidence yields PPV 10.1% — a primary-care rare-disease problem. StEP's 95%/93% pinprick figures come from specialist clinics where neuropathic pain is common. FibriCheck's 95.6%/96.6% is versus ECG after dropping poor signals. Blood-culture 99.4%/99.7% is laboratory identification, not community screening. Frailty's 99.1% specificity describes a ~1.1% trajectory class, not a test you run on everyone.
- Supports · How well does CA125 find ovarian cancer in GP care?
- Supports · StEP pain-subtype assessment
- Supports · Smartphone PPG to detect atrial fibrillation
- Supports · Rapid gram-positive blood culture ID
History
When this study was placed
Dated entries from the concept change log — when this paper was added or removed as support, challenge, or qualifier on a claim.
Placed as a scope qualifier on Diagnostic Accuracy
In UK Biobank, higher baseline plasma GFAP and NfL were associated with roughly doubled hazards of incident dementia over ~13 years, with incremental discrimination when added to demographic risk scores—prognostic biomarker performance, not a bedside diagnostic rule-in test.
Placed as supporting evidence on Diagnostic Accuracy
Other validated tools in this set include a point-of-care sickle-cell device detecting HbS/HbC at low percentages suitable for neonates, StEP pinprick signs highly sensitive/specific for neuropathic vs non-neuropathic pain in specialist clinics, and rapidly rising electronic frailty index trajectories associated with doubled 12-month mortality versus stable frailty.
Related papers in this topic
Same topic cluster — not a recommendation engine.